(0.10%) 5 522.50 points
(0.12%) 39 893 points
(0.23%) 19 796 points
(-0.01%) $81.62
(0.53%) $2.83
(-0.30%) $2 337.40
(0.07%) $29.55
(0.28%) $1 004.60
(0.00%) $0.931
(-0.03%) $10.53
(-0.01%) $0.788
(-0.88%) $87.22
8.11% $ 1.200
Live Chart Being Loaded With Signals
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases...
Stats | |
---|---|
Dzisiejszy wolumen | 473 049 |
Średni wolumen | 462 477 |
Kapitalizacja rynkowa | 106.25M |
EPS | $-0.810 ( Q1 | 2024-05-09 ) |
Następna data zysków | ( $-0.470 ) 2024-08-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.490 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00600 (0.50%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-06 | Alexander Robert | Sell | 37 525 | Common Stock |
2024-06-07 | Tomasi Adam | Sell | 24 749 | Common Stock |
2024-06-04 | Radford Harlan Baird | Sell | 14 565 | Common Stock |
2024-05-24 | Walker Paul Edward | Buy | 41 000 | Stock Option (Right to buy) |
2024-05-24 | Ladd Amy L | Buy | 41 000 | Stock Option (Right to buy) |
INSIDER POWER |
---|
57.63 |
Last 96 transactions |
Buy: 11 609 469 | Sell: 2 674 244 |
Wolumen Korelacja
Allakos Inc Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
OZEM | 1 |
OPTX | 0.881 |
BOLD | 0.873 |
FDBC | 0.857 |
BKYI | 0.856 |
VMAR | 0.838 |
ALTM | 0.836 |
ZKIN | 0.835 |
AEHR | 0.835 |
DADA | 0.832 |
10 Najbardziej negatywne korelacje | |
---|---|
BKHAR | -0.917 |
AXNX | -0.885 |
PPRUX | -0.871 |
SFBC | -0.854 |
IBAC | -0.834 |
FFNW | -0.823 |
ERNZ | -0.819 |
BLPH | -0.817 |
PRAX | -0.814 |
CLST | -0.813 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Allakos Inc Korelacja - Waluta/Towar
Allakos Inc Finanse
Annual | 2023 |
Przychody: | $0 |
Zysk brutto: | $-6.14M (0.00 %) |
EPS: | $-2.14 |
FY | 2023 |
Przychody: | $0 |
Zysk brutto: | $-6.14M (0.00 %) |
EPS: | $-2.14 |
FY | 2022 |
Przychody: | $0 |
Zysk brutto: | $-9.98M (0.00 %) |
EPS: | $-5.02 |
FY | 2021 |
Przychody: | $0.00 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-5.01 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Allakos Inc
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej